Buy Lithium Online

1 Lithium tablet contains: Lithium carbonate - 300 mg; Other ingredients: calcium stearate, potato starch, talc, povidone, hypromellose, titanium dioxide, polysorbate, tropeolin 0, talc.

Order Now

Pharmacological action

Lithium is a normothetic drug that normalizes the mental state without causing CNS retardation. Lithium has antidepressant, antimanic and sedative effects.

Lithium is a lithium drug, the mechanism of its action is associated with the ability of lithium ions to displace sodium ions from the cells (due to antagonism), as a result of which the bioelectrical activity of the CNS cells is reduced. Lithium promotes acceleration of degradation of biogenic amines, in particular norepinephrine and serotonin (due to which the levels of the latter in tissues decrease). Taking Lithium increases the sensitivity of cells in the hippocampus and other areas of the brain to dopamine.

Lithium interacts with the lipids that are formed during inositol metabolism. When taking therapeutic doses of Lithium, there is a decrease in the activity of inosyl-1-phosphatase and a decrease in the concentration of neuronal inositol, which is involved in the regulation of neuronal sensitivity.

Lithium also has a positive effect in migraine (the mechanism of action of lithium preparations in this case may be related to changes in serotonin levels). In depressive episodes, lithium preparations have a positive effect due to increased serotonergic activity and downregulation of beta-adrenoreceptor function.

lithium png

The active ingredient of the drug Lithium is well absorbed in the gastrointestinal tract when taken orally (fully absorbed in 6-8 hours and reaches peak levels in 1-3 hours). Lithium salts do not bind to serum proteins. The therapeutic dose corridor of Lithium is 0.6-1.2 mmol/l.

Equilibrium levels of lithium salts in serum are reached on day 4 from the start of treatment. There is a high degree of penetration of lithium through the placental and blood-brain barrier (levels of lithium in synovial fluid are 50% of those in the serum). During lactation, lithium is determined in breast milk.

The drug is not metabolized in the body. The elimination half-life of Lithium reaches 24 hours in adult patients, 18 hours in adolescent patients and 36 hours in patients over 65 years old. The half-life also depends on the level of sodium ions in the serum. Up to 95% of the administered dose of Lithium is excreted by the kidneys, up to 1% by the intestine and about 4-5% by the sweat glands. The degree of lithium excretion by the kidneys depends on the balance of lithium, sodium and potassium ions in the serum.

Great Assortment

24/7 Support

Worldwide Delivery

Indications for use

Lithium is used in the therapy of patients with hypomanic and manic states of various etiologies. Lithium can be used for affective disorders of alcohol etiology. Lithium is also used in therapy of patients with affective psychoses (including schizoaffective and manic-depressive psychosis). It is possible to use Lithium in therapy of patients with migraine, sexual disorders, Meniere's syndrome and some forms of drug addiction.

Lithium is taken orally, the daily dose is usually divided into 3-4 doses (the last dose should be appointed before going to bed). The drug Lithium should be taken after meals. The dosage of the drug Lithium and the duration of admission determines the specialist.

Usually Lithium is prescribed in the starting dose of 0.6-0.9 g / day. Later the dose can be increased to 1.2 g/day. If necessary, the dose is further titrated (increasing each time by no more than 0.3 g/day).

  • The average therapeutic dose of Lithium is 1.5-2.1 g/day.
  • The highest recommended dose is 2.4 g/day.
  • During dose titration, serum lithium level should be controlled (concentration should be within the range 0.6-1.2 mmol/l, but not more than 1.6 mmol/l).
  • It is allowed to use Lithium in shock doses (above 2 g/day) for not more than 2 weeks.

After manic symptoms are eliminated, the dose of drug Lithium should be gradually reduced to maintenance dose (the average maintenance dose of Lithium is 0.6-1.2 g/day). If against the background of reducing the daily dose of Lithium the patient regains symptoms of mania, it is necessary to return to the higher dose that gave the necessary therapeutic effect.

In acute manic states, serum lithium levels should be 0.8-1.2 mmol/l, while maintenance treatment should maintain serum lithium ion levels at 0.4-0.8 mmol/l. If a patient registers an increase in serum lithium levels above 1.2 mmol/L, the daily dose of Lithium should be reduced.

Prophylactic administration of Lithium (as monotherapy) usually gives an effect if the necessary lithium levels in serum (0.4-0.8 mmol/l) are maintained for 6 months or more.

In children, Lithium should be administered at a dose that enables serum lithium levels to be maintained at 0.5-1 mmol/l.

Serum lithium levels should be monitored weekly at the beginning of therapy (until stable concentrations are achieved), then serum lithium levels should be monitored monthly, if lithium levels are stable and dosage does not change - frequency of monitoring can be reduced to one every 2-3 months.
Blood samples for determination of lithium level should be taken in the morning (12 hours after the last dose taken at night or 24 hours after a single dose taken in the morning).


Lithium is contraindicated in patients with intolerance to lithium preparations or auxiliary components of the tablets. Lithium is not administered to patients who have recently undergone major surgery. Lithium is contraindicated in patients with leukemia.

Caution should be exercised when prescribing Lithium to patients with these conditions:

  • CPS abnormalities, including intraventricular block and atrial-ventricular block.
  • CNS disorders, including parkinsonism and epilepsy.
  • Thyrotoxicosis.
  • Diabetes mellitus.
  • Hyperparathyroidism.
  • Infectious diseases.
  • Renal insufficiency.
  • Psoriasis.

Water and electrolyte imbalances, including dehydration and hyponatremia, including in the presence of risk factors for these conditions (taking diuretics, salt-free diet, diarrhea and vomiting). During therapy with Lithium, avoid activities requiring high speed of psychomotor reactions.


In case of overdose of the drug Lithium patients are registered the development of somnolence, loss of appetite, nausea, muscle weakness, diarrhea. Some time after overdose, vagueness of vision, dizziness, impaired coordination of movements, confusion, polyuria and seizures may occur.

In cases of overdose of lithium preparations abundant drinking (or administration of a significant amount of fluid parenterally), as well as administration of sodium chloride (table salt) into the body is indicated.

Hospitalization is indicated for severe overdose. Form of production: Lithium tablets by 10 pieces in blister plates, 5 blister plates in a carton pack.